Back to search results

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Abroad (travel likely)RecruitingPHASE2

Conditions

Anatomic Stage I Breast Cancer · Anatomic Stage II Breast Cancer · Anatomic Stage III Breast Cancer · Invasive Breast Lobular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Emory University/ Winship Cancer Institute, Atlanta, Georgia, United States

    Contact: Principal Investigator (Kevin Kalinsky, MD)

  • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

    Contact: Principal Investigator (Adam Brufsky, MD)

  • Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

    Contact: Study coordinator (Vanderbilt-Ingram Service for Timely Access) · cip@vumc.org · 800-811-8480
    Contact: Principal Investigator (Laura Kennedy, MD, PhD)

  • University of Texas, Southwestern, Dallas, Texas, United States

    Contact: Study coordinator (Nisha Unni) · Nisha.Unni@UTSouthwestern.edu
    Carlos Arteaga, MD (Sub-investigator)
    Contact: Principal Investigator (Nisha Unni, MD)

  • Baylor College of Medicine, Houston, Texas, United States

    Contact: Principal Investigator (Bora Lim, MD)
Study leads

  • Laura Kennedy, MD, PhD

    Principal Investigator

    Vanderbilt University/Ingram Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)